Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes
Conclusion:
Dapagliflozin seemingly influences systemic and renal hemodynamics independently and beyond glucose lowering in people with type 2 diabetes.
This clinical trial was registered at https://clinicalTrials.gov (ID: NCT02682563).
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Hypertension | Iohexol | Omnipaque | Physiology | Reflex Sympathetic Dystrophy | SGLT2 Inhibitors | Stroke